Literature DB >> 32374000

An update on the status of COVID-19: a comprehensive review.

N Zhao1, Z-L Zhou, L Wu, X-D Zhang, S-B Han, H-J Bao, Y Shu, X-G Shu.   

Abstract

The last two decades have witnessed two large-scale pandemics caused by coronaviruses, including severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS). At the end of 2019, another novel coronavirus, designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hit Wuhan, a city in the center of China, and subsequently spread rapidly to the whole world. Latest reports revealed that more than 800 thousand people in over 200 countries are involved in the epidemic disease by SARS-CoV-2. Due to the high mortality rate and the lack of optimum therapeutics, it is crucial to understand the biological characteristics of the virus and its possible pathogenesis to respond to the SARS-CoV-2. Rapid diagnostics and effective therapeutics are also important interventions for the management of infection control. However, the rapid evolution of SARS-CoV-2 exerted tremendous challenges on its diagnostics and therapeutics. Therefore, there is an urgent need to summarize the existing research results to guide decision-making on the prioritization of resources for research and development. In this review, we focus on our current understanding of epidemiology, pathogenesis, diagnostics and therapeutics of coronavirus disease 2019 (COVID-19).

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32374000     DOI: 10.26355/eurrev_202004_21046

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  An Exit Strategy for Resuming Nonemergency Neurosurgery after Severe Acute Respiratory Syndrome Coronavirus 2: A United Kingdom Perspective.

Authors:  Ciaran S Hill; William R Muirhead; Vejay N Vakharia; Hani J Marcus; David Choi
Journal:  World Neurosurg       Date:  2020-06-04       Impact factor: 2.104

2.  COVID-19: Can the symptomatic SARS-CoV-2 infection affect the homeostasis of the gut-brain-microbiota axis?

Authors:  Marileia Chaves Andrade; Rodolfo Souza de Faria; Sergio Avelino Mota Nobre
Journal:  Med Hypotheses       Date:  2020-08-24       Impact factor: 1.538

3.  Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis.

Authors:  Joseph T Ortega; Maria Luisa Serrano; Beata Jastrzebska
Journal:  Biomolecules       Date:  2020-06-24

4.  Comparison of chest HRCT severity score in PCR positive and PCR negative clinically suspected COVID-19 Patients.

Authors:  Hina Hanif Mughal; Syed Muhammad Jawad Zaidi; Hamza Waqar Bhatti; Madiha Maryum; Maria Khaliq; Nasir Khan; Mehwish Kaneez
Journal:  Afr Health Sci       Date:  2021-12       Impact factor: 0.927

5.  Global Gene Expression and Docking Profiling of COVID-19 Infection.

Authors:  Almas Jabeen; Nadeem Ahmad; Khalid Raza
Journal:  Front Genet       Date:  2022-04-11       Impact factor: 4.772

6.  Elucidation of cellular targets and exploitation of the receptor-binding domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis.

Authors:  Abdul Mannan Baig; Areeba Khaleeq; Hira Syeda
Journal:  J Med Virol       Date:  2020-07-17       Impact factor: 20.693

7.  Symptoms in Health Care Workers during the COVID-19 Epidemic. A Cross-Sectional Survey.

Authors:  Nicola Magnavita; Giovanni Tripepi; Reparata Rosa Di Prinzio
Journal:  Int J Environ Res Public Health       Date:  2020-07-20       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.